Synergistic Effect of Combined HMG-CoA Reductase Inhibitor and Angiotensin-II Receptor Blocker Therapy in Patients With Chronic Heart Failure: The HF-COSTAR Trial

Background: It is known that HMG-CoA reductase inhibitors (statins) may have a therapeutic benefit in patients with heart failure (HF). However, no studies have yet evaluated the possible interaction of statins and angiotensin-II receptor blockers (ARBs) on left ventricular (LV) function in patients...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Circulation Journal 2011, Vol.75(3), pp.589-595
Hauptverfasser:	Maejima, Yasuhiro, Nobori, Kiyoshi, Ono, Yuichi, Adachi, Susumu, Suzuki, Jun-ichi, Hirao, Kenzo, Isobe, Mitsuaki, Ito, Hiroshi, for the Heart Failure by Coadministration of Statin and Angiotensin-II Receptor Blocker (HF-COSTAR) Trial Investigators
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Angiotensin Angiotensin Receptor Antagonists - pharmacology Angiotensin Receptor Antagonists - therapeutic use Chronic Disease Drug Synergism Drug Therapy, Combination Electrocardiography Female Heart failure Heart Failure - drug therapy Heart Failure - physiopathology Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Losartan - pharmacology Losartan - therapeutic use Male Middle Aged Pharmacology Prospective Studies Renin-Angiotensin System - drug effects Renin-Angiotensin System - physiology Simvastatin - pharmacology Simvastatin - therapeutic use Statin Treatment Outcome Ventricular Dysfunction, Left - drug therapy Ventricular Dysfunction, Left - physiopathology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!